Abstract:Background Autosomal recessive deafness 9, caused by mutations of the OTOF gene, is characterised by congenital or prelingual, severe-to-complete, bilateral hearing loss. However, no pharmacological treatment is currently available for congenital deafness. In this Article, we report the safety and efficacy of gene therapy with an adeno-associated virus (AAV) serotype 1 carrying a human OTOF transgene (AAV1-hOTOF) as a treatment for children with autosomal recessive deafness 9. Methods This single -arm, single -centre trial enrolled children (aged 1-18 years) with severe-to-complete hearing loss and confirmed mutations in both alleles of OTOF , and without bilateral cochlear implants. A single injection of AAV1-hOTOF was administered into the cochlea through the round window. The primary endpoint was dose-limiting toxicity at 6 weeks after injection. Auditory function and speech were assessed by appropriate auditory perception evaluation tools. All analyses were done according to the intention-to-treat principle. This trial is registered with Chinese Clinical Trial Registry, ChiCTR2200063181, and is ongoing. Findings Between Oct 19, 2022, and June 9, 2023, we screened 425 participants for eligibility and enrolled six children for AAV1-hOTOF gene therapy (one received a dose of 9 x 10 11 vector genomes [vg] and five received 15 x 10 12 vg). All participants completed follow-up visits up to week 26. No dose-limiting toxicity or serious adverse events occurred. In total, 48 adverse events were observed; 46 (96%) were grade 1-2 and two (4%) were grade 3 (decreased neutrophil count in one participant). Five children had hearing recovery, shown by a 40-57 dB reduction in the average auditory brainstem response (ABR) thresholds at 05-40 kHz. In the participant who received the 9 x 10 11 vg dose, the average ABR threshold was improved from greater than 95 dB at baseline to 68 dB at 4 weeks, 53 dB at 13 weeks, and 45 dB at 26 weeks. In those who received 15 x 10 12 AAV1-hOTOF, the average ABR thresholds changed from greater than 95 dB at baseline to 48 dB, 38 dB, 40 dB, and 55 dB in four children with hearing recovery at 26 weeks. Speech perception was improved in participants who had hearing recovery. Interpretation AAV1-hOTOF gene therapy is safe and efficacious as a novel treatment for children with autosomal recessive deafness 9.

AAV‐mediated Gene Therapy for Hereditary Deafness: Progress and Perspectives

Progress of Gene Therapy Based on AAV in Hereditary Deafness

AAV-Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness

Current AAV-mediated Gene Therapy in Sensorineural Hearing Loss

Recent advances and future challenges in gene therapy for hearing loss

Gene therapy for deafness

Advancements and future prospects of adeno-associated virus-mediated gene therapy for sensorineural hearing loss

Gene therapy for deafness: are we there now?

Audiological and Genetic Studies on Large Families with Non-Syndromic Deafness

Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges

Advances in Gene Therapy Hold Promise for Treating Hereditary Hearing Loss

Overloaded Adeno-Associated Virus as a Novel Gene Therapeutic Tool for Otoferlin-Related Deafness

Gene therapy for hearing loss: Current status and future prospects of non-viral vector delivery systems

Combined AAV-mediated gene replacement therapy improves auditory function in a mouse model of human DFNB42 deafness

Milestones toward cochlear gene therapy for patients with hereditary hearing loss

AAV-ie-K558R mediated cochlear gene therapy and hair cell regeneration

Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results

AAV1-hOTOF Gene Therapy for Autosomal Recessive Deafness 9: a Single-Arm Trial

Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success.

Application of Gene Therapy in Auditory System Diseases

Gene Therapy for Human Sensorineural Hearing Loss